Effect of plasma monocyte chemotactic factor-1 protein and matrix metalloproteinase-9 of patients with coronary artery disease following percutaneous coronary interventional procedures therapy

Objective To explore the change of monocyte chemotactic factor-1 protein（MCP-1）and matrix metalloproteinase-9（ MMP-9）of patients with coronary artery disease（ CAD）following percutaneous coronary interventional（ PCI）. Methods Fifty patients underwent PCI procedures for CAD compromising a single coronary artery were selected as PCI group and 30 healthy individuals with normal findings by coronary angiography were selected as the control group. Plasma MCP-1 and MMP-9 were measured in all the subjects. Results The plasma MCP-1 level of patients with CAD after PCI was（19. 87 ± 5. 31）ng/ L,higher than that before operation（（15. 71 ± 5. 23）ng/ L,t = 3. 95,P 〈 0. 01）. Whereas in the control group,the MCP-1 level after coronary angiography was（13. 78 ± 5. 58）ng/ L,which was as same as that before operation （12. 42 ± 5. 39 ng/ L,P = 0. 34）. Plasma MMP-9 level in the CAD patients after PCI procedures was（22. 69 ± 5. 97）mg/ L,higher than that before operation（（19. 52 ± 5. 72）mg/ L,t = 2. 71,P 〈 0. 01）. There was no significant difference in term of plasma MMP-9 level in control group befor and after operation（（17. 53 ± 5. 51） mg/ L vs.（16. 69 ± 5. 42）mg/ L,P = 0. 55）. Conclusion Plasma MCP-1 and MMP-9 increase in CAD patients following PCI procedures. But their roles in the vascular restenosis following the procedures need further investigation. Key words: Coronary artery disease; Percutaneous coronary interventional; Monocyte chemotactic factor-1 protein; Matrix metalloproteinase-9